| 151 |
21165580 | Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. | 2011 Mar |
1 |
| 152 |
21177407 | Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. | 2011 Apr 15 |
3 |
| 153 |
21206986 | ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. | 2011 Mar |
2 |
| 154 |
21286668 | Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. | 2011 Apr |
4 |
| 155 |
21298384 | Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. | 2011 Oct |
5 |
| 156 |
21315089 | The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. | 2011 Mar 15 |
1 |
| 157 |
21327329 | Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. | 2011 May |
2 |
| 158 |
21357694 | Novel role of base excision repair in mediating cisplatin cytotoxicity. | 2011 Apr 22 |
1 |
| 159 |
21364592 | CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. | 2011 Mar 29 |
3 |
| 160 |
21426588 | High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. | 2011 Mar 23 |
3 |
| 161 |
21521014 | SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. | 2011 Apr |
1 |
| 162 |
21586890 | [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. | 2011 Mar |
1 |
| 163 |
21621119 | Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. | 2011 Jul 1 |
2 |
| 164 |
21720251 | The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma. | 2011 Nov |
9 |
| 165 |
21750204 | Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. | 2011 Sep 1 |
1 |
| 166 |
21855036 | A review of excision repair cross-complementation group 1 in colorectal cancer. | 2011 Sep |
2 |
| 167 |
21902499 | Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. | 2011 Oct |
2 |
| 168 |
22199271 | ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. | 2011 Dec |
3 |
| 169 |
22977580 | ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer. | 2011 Sep |
1 |
| 170 |
19626585 | Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. | 2010 Apr 15 |
7 |
| 171 |
19940136 | The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. | 2010 Feb 5 |
1 |
| 172 |
19962780 | Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. | 2010 Aug |
7 |
| 173 |
20044377 | Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. | 2010 Jan 1 |
1 |
| 174 |
20085902 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. | 2010 Apr |
1 |
| 175 |
20189873 | Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. | 2010 Mar |
1 |
| 176 |
20332140 | ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. | 2010 Sep |
1 |
| 177 |
20372803 | Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. | 2010 May |
1 |
| 178 |
20403548 | [ERCC1 and lung cancer]. | 2010 Apr |
2 |
| 179 |
20443070 | Impact of biomarkers on non-small cell lung cancer treatment. | 2010 Mar |
2 |
| 180 |
20593954 | Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. | 2010 |
1 |
| 181 |
20622964 | Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. | 2010 Jun |
2 |
| 182 |
20677561 | [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy]. | 2010 Apr |
2 |
| 183 |
20689757 | MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. | 2010 Aug |
3 |
| 184 |
20823140 | Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. | 2010 Sep 15 |
4 |
| 185 |
20846399 | Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. | 2010 Sep 16 |
3 |
| 186 |
21029626 | [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer]. | 2010 Aug 10 |
4 |
| 187 |
21091775 | Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. | 2010 Dec |
3 |
| 188 |
21229648 | ERCC1 is not expressed in hepatocellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study. | 2010 Oct-Dec |
2 |
| 189 |
18804893 | Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. | 2009 May |
2 |
| 190 |
18823676 | Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. | 2009 Apr |
1 |
| 191 |
19123003 | Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. | 2009 Aug |
2 |
| 192 |
19267403 | Functional evidence for Eme1 as a marker of cisplatin resistance. | 2009 Jun 15 |
1 |
| 193 |
19473860 | Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. | 2009 Sep |
2 |
| 194 |
19620936 | Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. | 2009 Aug |
2 |
| 195 |
19832035 | The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. | 2009 Nov |
3 |
| 196 |
19900859 | Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. | 2009 Nov |
1 |
| 197 |
20066897 | Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro. | 2009 |
1 |
| 198 |
20082278 | Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. | 2009 Oct-Dec |
2 |
| 199 |
20719134 | [Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.]. | 2009 May 20 |
3 |
| 200 |
21475919 | Excision-repair cross-complementing 1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. | 2009 Nov-Dec |
2 |